ArticleHuman vaccines & immunotherapeutics2026
Immunity gap for measles in young adults: Seroprevalence study in blood donors in southern Italy.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Waning Measles Immunity and Sustained Rubella Seroprotection Among Adults in Istanbul, Türkiye.Medicina (Kaunas, Lithuania) · 2026Article
- Spatiotemporal Dynamics of the 2025-2026 Measles Outbreak in Mexico: Jalisco as the Emerging Epicenter and the Impact of Intensive Immunization Efforts.Pathogens (Basel, Switzerland) · 2026Article
- Assessment of Measles Immunity in the Croatian Population: A Retrospective Seroprevalence Study, 2015-2025.Vaccines · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following the COVID-19 pandemic, measles has seen a resurgence across Europe, including Italy. Increased vulnerability among young adults has raised concerns about waning vaccine-derived immunity. This study evaluated measles immunity among adult blood donors in the Apulia region to identify sero-susceptibility patterns and inform targeted public health strategies. A retrospective seroprevalence study was conducted using sera from 1579 healthy blood donors, aged 18 to 65 y, who attended donation centers in Apulia region between November 2023 and February 2024. Anti-measles virus (MV) IgG antibodies were measured using the ELISA test. Statistical analyses to identify associations between sero-susceptibility and demographic factors were performed. Overall seroprevalence of anti-MV IgG was 85.3% (95% CI: 83.4-87.0). The prevalence of sero-susceptibility varied significantly by age (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.